FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2046605287> ?p ?o ?g. }

• W2046605287 endingPage "3306" @default.
• W2046605287 startingPage "3297" @default.
• W2046605287 abstract "Four systems of nanoparticles of biodegradable polymers were developed in this research for oral delivery of anticancer drugs with Docetaxel used as a model drug, which include the poly(lactic-co-glycolic acid) nanoparticles (PLGA NPs), the poly(lactide)–vitamin E TPGS nanoparticles (PLA–TPGS NPs), the poly(lactic-co-glycolic acid)–montmorillonite nanoparticles (PLGA/MMT NPs) and the poly(lactide)–vitamin E TPGS/montmorillonite nanoparticles (PLA–TPGS/MMT NPs). Vitamin E TPGS stands for d-α-tocopheryl polyethylene glycol 1000 succinate (TPGS), which is a water-soluble derivative of natural vitamin E formed by esterification of vitamin E succinate with polyethylene glycol (PEG) 1000. The design was made to take advantages of TPGS in nanoparticle technology such as high emulsification effects and high drug encapsulation efficiency, and those in drug formulation such as high cellular adhesion and adsorption. MMT of similar effects is also a detoxifier, which may cure some side effects caused by the formulated drug. The drug-loaded NPs were prepared by a modified solvent extraction/evaporation method and then characterized for their MMT content, size and size distribution, surface charge and morphology, physical status and encapsulation efficiency of the drug in the NPs, and in vitro drug release profile. Cellular uptake of the coumarin 6-loaded NPs was investigated. In vitro cancer cell viability experiment showed that judged by IC50, the PLA–TPGS/MMT NP formulation was found 2.89, 3.98, 2.12-fold more effective and the PLA–TPGS NP formulation could be 1.774, 2.58, 1.58-fold more effective than the Taxotere® after 24, 48, 72 h treatment, respectively. In vivo PK experiment with SD rats showed that oral administration of the PLA–TPGS/MMT NP formulation and the PLA–TPGS NP formulation could achieve 26.4 and 20.6 times longer half-life respectively than i.v. administration of Taxotere® at the same 10 mg/kg dose. One dose oral administration of the NP formulations could realize almost 3 week sustained chemotherapy in comparison of 22 h of i.v. administration of Taxotere®. The oral bioavailability can be enhanced from 3.59% for Taxotere® to 78% for the PLA–TPGS/MMT NP formulation and 91% for the PLA–TPGS NP formulation respectively. Oral chemotherapy by nanoparticles of biodegradable polymers is feasible." @default.
• W2046605287 created "2016-06-24" @default.
• W2046605287 creator A5024300664 @default.
• W2046605287 creator A5034123119 @default.
• W2046605287 creator A5073739491 @default.
• W2046605287 creator A5088247833 @default.
• W2046605287 creator A5090841972 @default.
• W2046605287 date "2009-07-01" @default.
• W2046605287 modified "2023-10-15" @default.
• W2046605287 title "Poly(lactide)–vitamin E derivative/montmorillonite nanoparticle formulations for the oral delivery of Docetaxel" @default.
• W2046605287 cites W1565060818 @default.
• W2046605287 cites W1585705786 @default.
• W2046605287 cites W1782483823 @default.
• W2046605287 cites W1829549101 @default.
• W2046605287 cites W190801549 @default.
• W2046605287 cites W1966858550 @default.
• W2046605287 cites W1967974277 @default.
• W2046605287 cites W1976270581 @default.
• W2046605287 cites W1976301609 @default.
• W2046605287 cites W1979196526 @default.
• W2046605287 cites W1981281946 @default.
• W2046605287 cites W1983962811 @default.
• W2046605287 cites W1988505882 @default.
• W2046605287 cites W1995082650 @default.
• W2046605287 cites W2008186103 @default.
• W2046605287 cites W2022885537 @default.
• W2046605287 cites W2023409962 @default.
• W2046605287 cites W2037653676 @default.
• W2046605287 cites W2039123138 @default.
• W2046605287 cites W2040210681 @default.
• W2046605287 cites W2047611016 @default.
• W2046605287 cites W2059539152 @default.
• W2046605287 cites W2066522045 @default.
• W2046605287 cites W2068083571 @default.
• W2046605287 cites W2081914868 @default.
• W2046605287 cites W2084375116 @default.
• W2046605287 cites W2084535944 @default.
• W2046605287 cites W2091400260 @default.
• W2046605287 cites W2093495159 @default.
• W2046605287 cites W2095432319 @default.
• W2046605287 cites W2099314766 @default.
• W2046605287 cites W2128941584 @default.
• W2046605287 cites W2135920320 @default.
• W2046605287 cites W2141510260 @default.
• W2046605287 cites W2155315199 @default.
• W2046605287 cites W2184694295 @default.
• W2046605287 cites W2312605451 @default.
• W2046605287 cites W2413355409 @default.
• W2046605287 doi "https://doi.org/10.1016/j.biomaterials.2009.02.045" @default.
• W2046605287 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19299012" @default.
• W2046605287 hasPublicationYear "2009" @default.
• W2046605287 type Work @default.
• W2046605287 sameAs 2046605287 @default.
• W2046605287 citedByCount "273" @default.
• W2046605287 countsByYear W20466052872012 @default.
• W2046605287 countsByYear W20466052872013 @default.
• W2046605287 countsByYear W20466052872014 @default.
• W2046605287 countsByYear W20466052872015 @default.
• W2046605287 countsByYear W20466052872016 @default.
• W2046605287 countsByYear W20466052872017 @default.
• W2046605287 countsByYear W20466052872018 @default.
• W2046605287 countsByYear W20466052872019 @default.
• W2046605287 countsByYear W20466052872020 @default.
• W2046605287 countsByYear W20466052872021 @default.
• W2046605287 countsByYear W20466052872022 @default.
• W2046605287 countsByYear W20466052872023 @default.
• W2046605287 crossrefType "journal-article" @default.
• W2046605287 hasAuthorship W2046605287A5024300664 @default.
• W2046605287 hasAuthorship W2046605287A5034123119 @default.
• W2046605287 hasAuthorship W2046605287A5073739491 @default.
• W2046605287 hasAuthorship W2046605287A5088247833 @default.
• W2046605287 hasAuthorship W2046605287A5090841972 @default.
• W2046605287 hasConcept C13965031 @default.
• W2046605287 hasConcept C155672457 @default.
• W2046605287 hasConcept C171250308 @default.
• W2046605287 hasConcept C178790620 @default.
• W2046605287 hasConcept C181389837 @default.
• W2046605287 hasConcept C185592680 @default.
• W2046605287 hasConcept C192562407 @default.
• W2046605287 hasConcept C2776743539 @default.
• W2046605287 hasConcept C2776964284 @default.
• W2046605287 hasConcept C2779820397 @default.
• W2046605287 hasConcept C2780165375 @default.
• W2046605287 hasConcept C44228677 @default.
• W2046605287 hasConcept C45211672 @default.
• W2046605287 hasConcept C521977710 @default.
• W2046605287 hasConcept C71924100 @default.
• W2046605287 hasConcept C86181022 @default.
• W2046605287 hasConcept C98274493 @default.
• W2046605287 hasConceptScore W2046605287C13965031 @default.
• W2046605287 hasConceptScore W2046605287C155672457 @default.
• W2046605287 hasConceptScore W2046605287C171250308 @default.
• W2046605287 hasConceptScore W2046605287C178790620 @default.
• W2046605287 hasConceptScore W2046605287C181389837 @default.
• W2046605287 hasConceptScore W2046605287C185592680 @default.
• W2046605287 hasConceptScore W2046605287C192562407 @default.
• W2046605287 hasConceptScore W2046605287C2776743539 @default.
• W2046605287 hasConceptScore W2046605287C2776964284 @default.

• next